Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
CMPSLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET
CMPSLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspect
Compass Pathways to Participate in Two Investor Conferences in December
CMPSLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2
Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
CMPS(NASDAQ:CMPS) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of results from an open-label Phase 2 study evaluating the safety and tolerability of a single-dose of 25 mg of investigational COMP360 synthetic psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The Phase 2 study findings, previously disclosed in May
Compass Pathways to Participate in Four Investor Conferences in September
CMPSLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: Cantor Global Healthcare Conference – New York, NY: Fireside chat at 1:35 PM EST on September 3, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference – New York, NY: Fireside chat at 10:45 AM EST on September
Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA
CMPSLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Management will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA, with a company presentation scheduled at 4:00pm ET. A broadcast of Compass’s presentation will be accessible from the “Events” page of the Investors section of the Compass webs
Cantor Fitzgerald Assumes Compass Pathways at Overweight, Announces Price Target of $12
CMPS'Connecticut House Passes Psilocybin Decriminalization Bill To Remove Threat Of Jail For Possessing The Psychedelic' - Marijuana Moment
CMPSPoliticsExploring Psychedelic Medicine Is A 'Top Priority' For Trump Administration, FDA Commissioner Says - Marijuana Moment
CMPSVA Secretary Wants To Find Answers On Psychedelics Therapies For Veterans; Doug Collins Pointed Out That There Are 11 Trials Underway At The VA Into Use Of Psychedelics Like Psilocybin And MDMA - Politico
CMPSHC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $45 Price Target
CMPSCompass Pathways Expects 2025 Net Cash Used In Operating Activities To Be In The Range Of $120M-$145M
CMPSCompass Pathways Q1 EPS $(0.24) Beats $(0.47) Estimate, Cash $260.1M
CMPSCompass Pathways Partners With HealthPort To Advance Equitable Access To COMP360 Psilocybin Treatment For TRD
CMPSCompass Pathways Completes Dosing In Part A Of Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression
CMPSCompass Pathways Announced That All Participants Have Completed Dosing In Part A Of The COMP005 Phase 3 Trial For Treatment-Resistant Depression; The Company Is On Track To Disclose Top-line 6-week Primary Endpoint Results In Late June
CMPSCantor Fitzgerald Reiterates Overweight on Compass Pathwaysto Overweight
CMPSCompass Pathways Publishes Results From COMP360 Psilocybin Study Indicating Longer-Term antidepressant Effects With 25mg Dose
CMPSHC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $45 Price Target
CMPSCanaccord Genuity Maintains Buy on Compass Pathways, Lowers Price Target to $15
CMPSPsychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says
CMPSCompass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.
This Plumas Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
CMPSStifel Initiates Coverage On Compass Pathways with Buy Rating, Announces Price Target of $11
CMPSCompass Pathways Q4 2024 GAAP EPS $(0.63) Misses $(0.62) Estimate, Cash And Equivalents $165.1M
CMPSHC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $45
CMPSRBC Capital Reiterates Outperform on Compass Pathways, Maintains $18 Price Target
CMPSCompass Pathways Has Priced Its Underwritten Offering Of 24.01M American Depositary Shares To Certain Institutional Investors, Pre-funded Warrants To Purchase Up To 11.04M ADSs, At $4.275 Per ADS And Accompanying ADS Warrant, And $4.2649 Per Pre-funded Wa
CMPSFDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment
CMPSFDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.
Top 3 Health Care Stocks You'll Regret Missing In November
CMPSHC Wainwright & Co. Maintains Buy on Compass Pathways, Lowers Price Target to $60
CMPSMaxim Group Maintains Buy on Compass Pathways, Lowers Price Target to $12
CMPSRBC Capital Maintains Outperform on Compass Pathways, Lowers Price Target to $18
CMPSAs Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
CMPSCompass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus.
Compass Pathways Pushed Topline Data Readout From COMP005 Phase 3 Trial For COMP360 In Treatment-Resistant Depression To Q2 2025, And COMP006 Data Will Now Be Announced After 26-week Time Point, Expected In 2H Of 2026, Cuts Workforce By 30%
CMPSCompass Pathways Q3 2024 GAAP EPS $(0.56), Inline
CMPS2 New Studies Look At Compass Pathways' Psilocybin Drug For Anorexia And Depression
CMPSCompass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.
Transcript: Jason Raznick's Conversation with Mr. Wonderful Kevin O'Leary At The Benzinga Psychedelics Conference
CMPSOn this special edition of the RazReport, Benzinga Founder & CEO Jason Raznick sits down with Kevin O'Leary AKA Mr. Wonderful at the Benzinga Psychedelics Capital Conference to discuss why he's investing in psychedelics.
Landmark Gathering Of Psychedelics Executives And Scientists To Take Place In London May 11
CMPSAs the field of psychedelic medicine moves forward and international borders begin to open up, an expanding offering of conferences and live events are becoming available for investors, industry people and the general public.
